Antimicrobials against biofilm-based catheter-related infections: new perspectives
Abstract number: S454
Antimicrobials against biofilm-based catheter-related infections: new perspectives. In the last decades, different strategies have been developed to prevent microbial colonization of intravascular catheters through surface adsorption or incorporation in the device polymer matrix of antibiotic/antifungal agents. However, the currently available medicated catheters have shown to inhibit microbial biofilm formation for relatively short periods, mainly due to the massive release of the loaded antimicrobial agents in the first 24 h followed by a slow release at sub-inhibitory concentrations until drug exhaustion, this phenomenon involving the risk of emergence of antibiotic-resistant strains. To overcome these limitations, we focused our research efforts in developing different experimental approaches to prevent microbial colonization of central venous catheters based on the adsorption of antimicrobial agents to synthesized and properly functionalized polyurethanes with the aim to control drug adsorption and release. Firstly, we have impregnated appropriately functionalized polyurethanes with two antibiotics with different mechanisms of action, rifampicin and cefamandole nafate, along with pore forming agents such as albumin and polyethylene glycol. This in vitro model exhibited a good polymer/antibiotic affinity and the ability to obtain a controlled release of large amounts of antimicrobials for up to 23 days. These results suggest that the entrapping of antibiotic molecules and pore-formers in properly functionalized polyurethanes may represent a promising approach to prevent catheter colonization and onset of bacterial resistance. Other antibiofilm strategies we are dealing with concern: i) the development of antimicrobial polymers by the use of polyurethanes able to coordinate metal ions (Ag+, Zn2+, etc); ii) the exploiting of the biofilm matrix-degrading enzyme, Dispersin B, to allow a better penetration of antibiotics through the microbial biofilm, thus improving their activity; iii) the development of a magnetic nanoparticles-based targeting system to fight catheter-related infections by an in situ, on demand, antimicrobial treatment.
|Session name:||Abstracts 20th European Congress of Clinical Microbiology and Infectious Diseases|
|Location:||Vienna, Austria, 10 - 13 April 2010|
|Back to top|